Wall Street analysts expect Orthopediatrics Corp (NASDAQ:KIDS) to announce $15.09 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Orthopediatrics’ earnings, with the lowest sales estimate coming in at $15.07 million and the highest estimate coming in at $15.10 million. Orthopediatrics posted sales of $12.38 million in the same quarter last year, which suggests a positive year-over-year growth rate of 21.9%. The firm is expected to issue its next earnings results on Wednesday, November 14th.

On average, analysts expect that Orthopediatrics will report full-year sales of $56.48 million for the current financial year, with estimates ranging from $56.40 million to $56.60 million. For the next year, analysts forecast that the business will report sales of $68.02 million per share, with estimates ranging from $66.00 million to $69.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.27 million. Orthopediatrics had a negative net margin of 61.99% and a negative return on equity of 192.23%. The firm’s revenue for the quarter was up 28.0% compared to the same quarter last year.

A number of equities research analysts have weighed in on KIDS shares. BidaskClub downgraded Orthopediatrics from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Piper Jaffray Companies lifted their price objective on Orthopediatrics from $24.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, July 5th. William Blair reaffirmed an “outperform” rating on shares of Orthopediatrics in a report on Wednesday, June 27th. Zacks Investment Research downgraded Orthopediatrics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 14th. Finally, ValuEngine raised Orthopediatrics from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $25.67.

In other news, General Counsel Daniel J. Gerritzen sold 9,525 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $33.73, for a total value of $321,278.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kevin Unger sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $33.22, for a total value of $33,220.00. The disclosure for this sale can be found here. 46.10% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wasatch Advisors Inc. raised its position in Orthopediatrics by 70.1% in the 2nd quarter. Wasatch Advisors Inc. now owns 401,049 shares of the company’s stock worth $10,684,000 after purchasing an additional 165,234 shares during the last quarter. BlackRock Inc. raised its position in Orthopediatrics by 74.9% in the 2nd quarter. BlackRock Inc. now owns 341,196 shares of the company’s stock worth $9,090,000 after purchasing an additional 146,115 shares during the last quarter. First Light Asset Management LLC bought a new position in Orthopediatrics in the 1st quarter worth approximately $1,750,000. Royce & Associates LP raised its position in Orthopediatrics by 66.0% in the 2nd quarter. Royce & Associates LP now owns 182,600 shares of the company’s stock worth $4,864,000 after purchasing an additional 72,600 shares during the last quarter. Finally, Cortina Asset Management LLC raised its position in Orthopediatrics by 54.0% in the 1st quarter. Cortina Asset Management LLC now owns 199,269 shares of the company’s stock worth $3,001,000 after purchasing an additional 69,884 shares during the last quarter. 40.17% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ KIDS traded up $0.14 during trading on Friday, reaching $32.50. 837 shares of the company traded hands, compared to its average volume of 46,315. The company has a current ratio of 5.98, a quick ratio of 3.61 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $424.13 million and a price-to-earnings ratio of -5.71. Orthopediatrics has a 1-year low of $14.00 and a 1-year high of $35.50.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Recommended Story: Diversification

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.